Nobias
Nobias Therapeutics focuses on developing advanced therapeutics for pediatric and rare diseases using AI and deep learning tools, with notable candidates NB-001 and NB-002 in clinical and pre-clinical stages respectively.
Company Overview
Nobias is a company dedicated to developing advanced therapeutics for pediatric and rare diseases. By integrating clinical, molecular, and genomic datasets, Nobias identifies therapeutic targets and creates optimal molecules and tools. The company operates locations in Mountain View, California, and Philadelphia, Pennsylvania, and offers both on-site and fully remote roles.
AI-Driven Drug Discovery
Nobias utilizes sophisticated deep learning tools and algorithms to analyze clinical, genomic, and molecular datasets. This approach aids in distilling disease drivers and identifying points for therapeutic intervention. The company leverages its proprietary Nobias WorkbenchTM, a suite of AI/ML-based drug discovery tools, to facilitate this process.
Proprietary Genomic Datasets
Nobias has proprietary access to a vast and diverse pediatric genomic dataset, considered one of the world's largest. This access enables the company to perform in-depth analyses and develop precise therapeutics for pediatric and rare diseases.
Breakthrough Therapies
Nobias has developed two candidate breakthrough therapies for rare pediatric diseases. NB-001, an investigational mGluR modulator for neuropsychiatric symptoms of 22q11.2 Deletion Syndrome (22q11DS), is in Phase 2 clinical trials. Results from the trial showed that NB-001 is safe and well-tolerated, with efficacy trends supporting further trials. NB-002, a MEK inhibitor for vascular anomalies, is currently in pre-clinical development.
Recent Clinical Trial Results
At the 52nd Child Neurology Society Annual Meeting, Nobias announced Phase 2 clinical trial results for NB-001. The trial met its primary endpoint, demonstrating that NB-001 is safe and well-tolerated. Secondary endpoints indicated efficacy trends, with improvements in CGI-I scores for ADHD, anxiety, and autism symptoms compared to baseline scores.